A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 143

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 143
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 209
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3098
Function: getPubMedXML

File: /var/www/html/application/controllers/Detail.php
Line: 574
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 488
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Attempt to read property "Count" on bool

Filename: helpers/my_audit_helper.php

Line Number: 3100

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3100
Function: _error_handler

File: /var/www/html/application/controllers/Detail.php
Line: 574
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 488
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. | LitMetric

Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.

Clin Cancer Res

Department of Medicine, Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, Moores Cancer Center, San Diego, California.

Published: April 2017

Aberrations in genetic sequences encoding the tyrosine kinase receptor RET lead to oncogenic signaling that is targetable with anti-RET multikinase inhibitors. Understanding the comprehensive genomic landscape of aberrations across multiple cancers may facilitate clinical trial development targeting We interrogated the molecular portfolio of 4,871 patients with diverse malignancies for the presence of aberrations using Clinical Laboratory Improvement Amendments-certified targeted next-generation sequencing of 182 or 236 gene panels. Among diverse cancers, aberrations were identified in 88 cases [1.8% (88/4, 871)], with mutations being the most common alteration [38.6% (34/88)], followed by fusions [30.7% (27/88), including a novel ] and amplifications [25% (22/88)]. Most patients had coexisting aberrations in addition to anomalies [81.8% (72/88)], with the most common being in -associated genes [59.1% (52/88)], cell cycle-associated genes [39.8% (35/88)], the PI3K signaling pathway [30.7% (27/88)], MAPK effectors [22.7% (20/88)], or other tyrosine kinase families [21.6% (19/88)]. fusions were mutually exclusive with MAPK signaling pathway alterations. All 72 patients harboring coaberrations had distinct genomic portfolios, and most [98.6% (71/72)] had potentially targetable coaberrations with either an FDA-approved or an investigational agent. Two cases with lung () and medullary thyroid carcinoma ( M918T) that responded to a vandetanib (multikinase RET inhibitor)-containing regimen are shown. aberrations were seen in 1.8% of diverse cancers, with most cases harboring actionable, albeit distinct, coexisting alterations. The current report suggests that optimal targeting of patients with anomalies will require customized combination strategies. .

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-1679DOI Listing

Publication Analysis

Top Keywords

diverse cancers
12
next-generation sequencing
8
4871 patients
8
tyrosine kinase
8
signaling pathway
8
aberrations
7
patients
5
aberrations diverse
4
cancers
4
cancers next-generation
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!